Heron Therapeutics, Inc.
HRTX
$1.36
-$0.05-3.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 74.22% | 183.39% | 134.16% | 80.61% | 78.04% |
| Total Depreciation and Amortization | -4.68% | -20.03% | -18.74% | -20.08% | -13.26% |
| Total Amortization of Deferred Charges | 43.06% | 50.71% | 84.05% | 416.44% | 176.92% |
| Total Other Non-Cash Items | -63.03% | -24.46% | -48.22% | -53.73% | -47.01% |
| Change in Net Operating Assets | -250.41% | -43.31% | -318.32% | -50.13% | -986.53% |
| Cash from Operations | -136.06% | 6.79% | -579.84% | 136.73% | 83.05% |
| Capital Expenditure | 67.35% | -- | -155.20% | 45.65% | -129.14% |
| Sale of Property, Plant, and Equipment | -- | -- | 107.69% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 180.48% | 83.10% | 239.89% | 119.62% | -80.11% |
| Cash from Investing | 258.11% | 77.86% | 229.22% | 117.10% | -84.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 235.43% | -- | 110.45% | -99.95% | -75.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -38.80% | 481.82% | -- | -- | 182.34% |
| Cash from Financing | 58.74% | 481.82% | 112.56% | -99.97% | 54.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.38% | 20.59% | 100.99% | -65.63% | 84.85% |